Drug Type Small molecule drug |
Synonyms 3,4-Dihydroxycinnamic acid, CABE |
Target |
Action modulators |
Mechanism BAX modulators(Apoptosis regulator BAX modulators), Bcl-2 modulators(Apoptosis regulator Bcl-2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC9H8O4 |
InChIKeyQAIPRVGONGVQAS-UHFFFAOYSA-N |
CAS Registry331-39-5 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Caffeic Acid | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | - | 01 Aug 2025 | |
| Nerve injury | Preclinical | China | 01 May 2025 | |
| Psoriasis | Preclinical | - | - | |
| Psoriasis | Preclinical | - | - |
Phase 2 | Purpura, Thrombocytopenic, Idiopathic First line | 214 | Caffeic acid tablets plus high-dose dexamethasone | lwyavxyogw(bzijntoqzb) = The most commonly observed adverse events (AEs) in both groups were gastrointestinal symptoms, anxiety or mood disorders, and fatigue, without statistically significant differences. No grade 4 or worse AEs or death occurred. fejewfgeoc (jttfkvjllm ) View more | Positive | 22 Aug 2025 | |
Placebo plus high-dose dexamethasone |





